leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma says Health Canada has confirmed LSD derivative 2-bromo-LSD is not a controlled substance

The confirmation clears the bath for BetterLife to begin IND-enabling pre-clinical studies of its psychedelic product TD-0148A

BetterLife Pharma Inc -
2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD without the psychedelic effects

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) announced Tuesday that Health Canada has confirmed that LSD derivative 2-bromo-LSD is not classified as a controlled substance.

In a statement, CEO Ahmad Doroudian told shareholders that confirmation of the status is a “significant first step” for the Vancouver-based company to begin its IND-enabling pre-clinical studies of its psychedelic product TD-0148A.

As a result, BetterLife will not face major regulatory hurdles during the development process of TD-0148A that other psychedelic products will encounter, according to Doroudian.

READ: BetterLife Pharma seeks patent protection for new 2-Bromo-LSD formulations to treat depression and mood disorders

“We believe that there is a great need for novel non-hallucinogenic treatments of mental disorders that can be dispensed at the pharmacy level and safely administered at home. BetterLife’s TD-0148A is one such treatment,” Doroudian told investors.

2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations. BetterLife is developing the formulation to help tread depression and mood disorders.

Doroudian was quoted in a recent edition of Forbes magazine emphasizing the challenges that current regulations impose on the development of psychedelics and LSD-based compounds.

BetterLife also develops drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus (COVID-19) and human papillomavirus, or to directly inhibit tumors to treat specific types of cancer.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: BetterLife Pharma Inc

Price: 1.16 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $58.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 10/16/2020

2 min read